# Ptc Therapeutics (PTCT): value investors who own it

1 value investor held Ptc Therapeutics in their Q3 2026 13F, led by Polen Capital Management.

## 13F holders

| Manager | Portfolio | Value | Change | Quarters held |
| --- | --- | --- | --- | --- |
| Polen Capital Management | 0.0% | $2.0m | New | 1 |

## Directors buying and selling (Form 4, last 12 months)

| Date | Who | Role | Bought or sold | Shares | Value |
| --- | --- | --- | --- | --- | --- |
| 2026-10-14 | SCHMERTZLER MICHAEL | Director | Sold | 2118 | $126k |
| 2026-10-14 | SCHMERTZLER MICHAEL | Director | Sold | 382 | $23k |
| 2026-10-09 | Boulding Mark Elliott | EXEC. VP AND CLO | Sold | 192 | $12k |
| 2026-10-07 | SCHMERTZLER MICHAEL | Director | Sold | 2447 | $155k |
| 2026-10-07 | SCHMERTZLER MICHAEL | Director | Sold | 53 | $3k |
| 2026-10-06 | Boulding Mark Elliott | EXEC. VP AND CLO | Sold | 435 | $28k |
| 2026-10-05 | Boulding Mark Elliott | EXEC. VP AND CLO | Sold | 1638 | $105k |
| 2026-09-30 | STEELE GLENN JR MD PHD | Director | Sold | 12000 | $782k |
| 2026-09-17 | SCHMERTZLER MICHAEL | Director | Sold | 9624 | $653k |
| 2026-09-17 | SCHMERTZLER MICHAEL | Director | Sold | 376 | $26k |
| 2026-09-16 | SCHMERTZLER MICHAEL | Director | Sold | 7006 | $472k |
| 2026-09-16 | SCHMERTZLER MICHAEL | Director | Sold | 2994 | $199k |
| 2026-09-10 | SCHMERTZLER MICHAEL | Director | Sold | 10000 | $673k |
| 2026-09-09 | SCHMERTZLER MICHAEL | Director | Sold | 9428 | $639k |
| 2026-09-09 | SCHMERTZLER MICHAEL | Director | Sold | 572 | $39k |
| 2026-08-27 | SCHMERTZLER MICHAEL | Director | Sold | 11890 | $851k |
| 2026-08-27 | SCHMERTZLER MICHAEL | Director | Sold | 610 | $44k |
| 2026-08-26 | SCHMERTZLER MICHAEL | Director | Sold | 6874 | $500k |
| 2026-08-26 | SCHMERTZLER MICHAEL | Director | Sold | 5626 | $412k |
| 2026-08-20 | SCHMERTZLER MICHAEL | Director | Sold | 9419 | $667k |

Source: SEC filings, via moatshark (https://www.moatshark.com/s/ptct). Values traded and returns are estimates. Not investment advice. Built 2026-10-21.